A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Differentiation, Maintenance, and Analysis of Human Retinal Pigment Epithelium Cells: A Disease-in-a-dish Model for BEST1 Mutations

6.3K views

⸱

DOI:

10.3791/57791

⸱

August 24th, 2018

 ,  ,  , 

In This Article

Summary

Here we present a protocol to differentiate retinal pigment epithelium (RPE) cells from human pluripotent stem cells bearing patient-derived mutations. The mutant cell lines may be used for functional analyses including immunoblotting, immunofluorescence, and patch clamp. This disease-in-a-dish approach circumvents the difficulty of obtaining native human RPE cells.

Abstract

Although over 200 genetic mutations in the human BEST1 gene have been identified and linked to retinal degenerative diseases, the pathological mechanisms remain elusive mainly due to the lack of a good in vivo model for studying BEST1 and its mutations under physiological conditions. BEST1 encodes an ion channel, namely BESTROPHIN1 (BEST1), which functions in retinal pigment epithelium (RPE); however, the extremely limited accessibility to native human RPE cells represents a major challenge for scientific research. This protocol describes how to generate human RPEs bearing BEST1 disease-causing mutations by induced differentiation from human pluripotent stem cells (hPSCs). As hPSCs are self-renewable, this approach allows researchers to have a steady source of hPSC-RPEs for various experimental analyses, such as immunoblotting, immunofluorescence, and patch clamp, and thus provides a very powerful disease-in-a-dish model for BEST1-associated retinal conditions. Notably, this strategy can be applied to study RPE (patho)physiology and other genes of interest natively expressed in RPE.

Introduction

It has been documented that at least five retinal degenerative diseases are caused by genetic mutations in the BEST1 gene1,2,3,4,5,6,7,8, with the number of reported mutations already over 200 and still increasing. These BEST1-associated diseases, also known as bestrophinopathies, cause progressive vision loss and even blindness, and there are currently no effective treatments. The prot....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Differentiation of hPSC to RPE

  1. Maintain and passage hPSCs as previously described18.
    NOTE: All cells (including hPSCs and hPSC-RPEs) are grown in 37 °C at 5% CO2 throughout the duration of the growth and differentiation protocols.
  2. Prior to differentiation, split confluent hPSCs to pre-coated 6-well plates.
    1. To coat plates, thaw basement membrane matrix on ice for about 1 h, suspend liquidized matrix in 4 °C DMEM medium at a 1:50 dilution, add 800 µL coating mixture to each well, and incubate for at least 1 h at 37 °C.
    2. When coating is complete, ....

Access restricted. Please log in or start a trial to view this content.

Results

The most technically challenging step is the manual isolation, which aims to achieve a high purity of a differentiated P0 hPSC-RPE population. After a successful isolation, >90% cells in the P0 population will grow and mature to display signature RPE morphologies (Figure 1C). The existence of a minor portion of non-RPE or immature RPE cells in the P0 population is almost inevitable, but will not interfere with the downstrea.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The most important procedure for the disease-in-a-dish approach is to differentiate hPSCs with a disease-causing mutation to the correct cell lineage, which is RPE for BEST1. Thus, after each differentiation experiment, the resulting hPSC-RPE cells should be carefully validated for their mature status by RPE-specific morphologies and protein markers16,17,18. To minimize clonal artifact, multiple hiPSC clones from the sa.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This project was funded by NIH grants EY025290, GM127652, and University of Rochester start-up funding.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Knock-Out (KO) DMEMThermoFisher10829018
KO serum replacementThermoFisher10829028
Nonessential amino acidsThermoFisher11140050
GlutamineThermoFisher35050061
Penicillin-streptomycinThermoFisher10378016
NicotinamideSigma-AldrichN0636
Human activin-APeproTech120-14
MEM (a modification)Sigma-AldrichM4526
Fetal Bovine SerumVWR97068-085
N1 supplementSigma-AldrichN6530
Glutamine-penicillin-streptomycinSigma-AldrichG1146
Nonessential amino acidsSigma-AldrichM7156
TaurineSigma-AldrichT0625
HydrocortisoneSigma-AldrichH0386
Triiodo-thyroninSigma-AldrichT5516
mTeSR-1 mediumStemcell Technologies5850
MatrigelCorning356230
CollagenaseGibco17104019
TrypsinVWR45000-664
M-PER mammalian protein extraction reagentPierce78501
proteinase inhibitor cocktailSigma-Aldrich4693159001
RPE65 antibodyNovus BiologicalsNB100-355
CRALBP antibodyAbcamab15051
BEST1 antibodyNovus BiologicalsNB300-164
Beta Actin antibodyThermoFisherMA5-15739
Alexa Fluor 488-conjugated donkey anti-mouse IgGThermoFisherA-21202
Goat anti-mouse IgGThermoFisherSA5-35521
Goat anti-Rabbit IgGLI-COR Biosciences926-68071
Hoechst 33342ThermoFisher62249
HEKA EPC10 patch clamp amplifierWarner Instruments895000
PatchmasterWarner Instruments895040

References

  1. Allikmets, R., et al. Evaluation of the Best disease gene in patients with age-related macular degeneration and other maculopathies. Hum Genet. 104 (6), 449-453 (1999).
  2. Burgess, R., et al. Biallelic mutation of BEST1 causes ....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Pluripotent Stem Cell DifferentiationRPE Cell IsolationWhole-cell Patch ClampImmunoblotting AnalysisImmunofluorescence StainingStromal Vascular FractionCell Culture Protocol